BIBW 2992 is a novel tyrosine kinase inhibitor that acts by irreversibly blocking the EGFR /HER2 receptors, which are promoters of tumour growth. BIBW 2992 has demonstrated preclinical activity against erlotinib and gefitinib resistant mutations.
Under the terms of the agreement, DxS and Boehringer Ingelheim will work jointly to make a suitable companion diagnostic test kit, to be available globally.
Dr. Stephen Little, CEO of DxS, said: “This is another great endorsement of our companion diagnostic assays for predicting patient response to targeted therapies. It is an exciting step forward for personalised medicine and DxS is pleased to be at the forefront of this revolution in cancer treatment”.